opioid withdrawal. Mental and behavioural disorders due to use of opioids / Dependence syndrome
Conditions
Interventions
Intervention 1: drug group: patients recieved 250 mg oral capsule of ginseng twice daily for 15 days along with MMT protocol. Intervention 2: placebo group: patients recieved placebo oral capsule of g
Treatment - Drugs
Placebo
drug group: patients recieved 250 mg oral capsule of ginseng twice daily for 15 days along with MMT protocol.
placebo group: patients recieved placebo oral capsule of gensing twice daily for 15 days along with MMT protocol.
Sponsors
Pharmaceutical sciences branch of Islamic Azad university
Eligibility
Sex/Gender
Male
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: Iinclusion criteria: -all patients were male abusing opioids for at least 1 year -age range was between 18 and 50. -all patients were at the beginning of induction phase of MMT protocol -subjects should not recieve any other medication which affects withdrawal symptoms. Exclusion criteria: -incidence of any allergic effect to ginseng or other ingredients of capsules -patient unlikely to continue the intervention -positive urine tests indicating abuse of any opioid or stimulant drug -missing more than 1 dose of ginseng or a day of methadone treatment
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical opioid withdrawal symptoms. Timepoint: days 0,1,7,10,15. Method of measurement: clinical opioid withdrawal scale. | — |
Secondary
| Measure | Time frame |
|---|---|
| Methadone dosage. Timepoint: every day. Method of measurement: base on ducuments and patients records. | — |
Countries
Iran (Islamic Republic of)
Outcome results
None listed